Molecular Testing in Thyroid Cancer

摘要: Cancer of the thyroid gland is associated with genetic aberrations including point mutations in BRAF, RET, and any RAS subtypes chromosomal translocations involving known breakpoints RET/PTC PAX8/PPARγ. While relationships between these molecular abnormalities tumor carcinogenesis have been well characterized, their relationship to prognosis usefulness clinical care less clear. In this chapter, we discuss aberrations, how they are detected, correlate cytomorphological histomorphological findings, useful constellation information may be current patient management. We also compare contrast currently available testing strategies—the gene expression classifier somatic mutation panel—for stratifying risk cytomorphologically indeterminate nodules biopsied by fine needle aspiration.